Meloxicam with Filgrastim may Reduce Oxidative Stress in Hematopoietic Progenitor Cells during Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Multiple Myeloma

Patterson, Andrea M.; Zhang, Shuhong; Liu, Liqiong; Li, Hongge; Singh, Pratibha; Liu, Yunlong; Farag, Sherif; Pelus, Louis M.

doi:10.1007/s12015-021-10259-y

Cited by 3 publications

(1 citation statement)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meloxicam, a COX1/COX2 inhibitor with selectivity for COX2, mobilized higher numbers of CD34 þ cells when combined with G-CSF in patients with MM compared to G-CSF alone and reduced the need for plerixafor as a rescue strategy for poorly mobilizing patients [95]. Patients required fewer apheresis days to collect sufficient CD34 þ cells (NCT02003625), and the quality of HSCs may be superior to those mobilized with G-CSF alone [96]. The effects of chronic nonsteroidal anti-inflammatory use on HSC mobilization in patients with SCD are not known.…”

Section: New Drugs Hematopoietic Stem Cell Mobilizationmentioning

confidence: 99%

Hematopoietic stem cell collection for sickle cell disease gene therapy

Leonard,

Weiss

2024

Current Opinion in Hematology

View full text Add to dashboard Cite

Purpose of review Gene therapy for sickle cell disease (SCD) is advancing rapidly, with two transformative products recently approved by the US Food and Drug Administration and numerous others under study. All current gene therapy protocols require ex vivo modification of autologous hematopoietic stem cells (HSCs). However, several SCD-related problems impair HSC collection, including a stressed and damaged bone marrow, potential cytotoxicity by the major therapeutic drug hydroxyurea, and inability to use granulocyte colony stimulating factor, which can precipitate severe vaso-occlusive events. Recent findings Peripheral blood mobilization of HSCs using the CXCR4 antagonist plerixafor followed by apheresis collection was recently shown to be safe and effective for most SCD patients and is the current strategy for mobilizing HSCs. However, exceptionally large numbers of HSCs are required to manufacture an adequate cellular product, responses to plerixafor are variable, and most patients require multiple mobilization cycles, increasing the risk for adverse events. For some, gene therapy is prohibited by the failure to obtain adequate numbers of HSCs. Summary Here we review the current knowledge on HSC collection from individuals with SCD and potential improvements that may enhance the safety, efficacy, and availability of gene therapy for this disorder.

show abstract

Section: New Drugs Hematopoietic Stem Cell Mobilizationmentioning

confidence: 99%

Hematopoietic stem cell collection for sickle cell disease gene therapy

Leonard,

Weiss

2024

Current Opinion in Hematology

View full text Add to dashboard Cite

show abstract

The efficacy of residual plerixafor for second-day stem cell mobilization in multiple myeloma patients

He¹,

Zhu²,

Xia

et al. 2023

Transfusion and Apheresis Science

View full text Add to dashboard Cite

Modulation of Cellular Redox Parameters for Improving Therapeutic Responses in Multiple Myeloma

et al. 2022

View full text Add to dashboard Cite

Raised oxidative stress and abnormal redox status are typical features of multiple myeloma cells, and the identification of the intimate mechanisms that regulate the relationships between neoplastic cells and redox homeostasis may reveal possible new anti-myeloma therapeutic targets to increase the effectiveness of anti-myeloma drugs synergistically or to eradicate drug-resistant clones while reducing toxicity toward normal cells. An alteration of the oxidative state is not only responsible for the onset of multiple myeloma and its progression, but it also appears essential for the therapeutic response and for developing any chemoresistance. Our review aimed to evaluate the literature’s current data on the effects of oxidative stress on the response to drugs generally employed in the therapy of multiple myeloma, such as proteasome inhibitors, immunomodulators, and autologous transplantation. In the second part of the review, we analyzed the possibility of using other substances, often of natural origin, to modulate the oxidative stress to interfere with the progression of myelomatous disease.

show abstract

Meloxicam with Filgrastim may Reduce Oxidative Stress in Hematopoietic Progenitor Cells during Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Multiple Myeloma

Cited by 3 publications

References 75 publications

Hematopoietic stem cell collection for sickle cell disease gene therapy

Hematopoietic stem cell collection for sickle cell disease gene therapy

The efficacy of residual plerixafor for second-day stem cell mobilization in multiple myeloma patients

Modulation of Cellular Redox Parameters for Improving Therapeutic Responses in Multiple Myeloma

Contact Info

Product

Resources

About